Project Grant HT94252310148

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

Paramita Therapeutics Inc. received a $353,009 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), awarded September 24, 2025, with completion targeted for August 31, 2026. The project focuses on developing novel multivalent prostate-specific membrane antigen (PSMA)-targeted taxane-conjugates to address bone metastases in prostate cancer. The research involves synthesizing multivalent drug conjugates (MDCs)...

Federal Project Grant Summary The University of Pittsburgh received a $658,492 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 18, 2026 through February 28, 2031. The research focuses on developing a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC), including castration-resistant prostate cancer with adenocarcinoma (CRPC-Adeno) and neuroendocrine prostate cancer...

Federal Project Grant Award Summary The University of Toledo Health Science Campus Division received a $418,822 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop selective allosteric modulators targeting the PTH1R (parathyroid hormone receptor type 1) pathway for treating prostate cancer bone metastases. The award, effective May 1, 2026 through April 30, 2028, supports the identification and evaluation of novel small...

Federal Project Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 20, 2026, with a completion date of February 28, 2031. The award supports a randomized Phase 2 clinical trial investigating blood-based tumor and immune markers to optimize treatment decisions in patients with oligometastatic castration-sensitive prostate cancer (OMCSPC). The research will...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,927,373.00 to the Fred Hutchinson Cancer Center in Seattle, WA to support the "Development of Targeted Therapies for Metastatic Prostate Cancers Classified by Subtypes of DNA Repair Deficiency". The 3-year project aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader...

This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...

Federal Grant Award Summary The National Cancer Institute, under its Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded a $575,178 Project Grant to The Regents of the University of California, San Francisco on May 15, 2026, with an ultimate completion date of April 30, 2031. This award funds the development and validation of a novel radiopharmaceutical platform termed "Restricted Interaction Peptides" (RIPs) designed to enhance molecularly targeted radiotherapy...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

Federal Project Grant Award Summary The University of California, San Diego received a $410,933 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period March 18, 2026 through February 29, 2028. This high-risk/high-impact exploratory research grant supports the development of next-generation small interfering RNA (siRNA) therapeutics designed to enhance cellular delivery of siRNA molecules into metastatic castration-resistant...